AstraZeneca (AZN) Tops Q1 EPS by $1.06

AstraZeneca (NASDAQ: AZN) reported Q1 EPS of $1.89, $1.06 better than the analyst estimate of $0.83. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $10.99 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
• AstraZeneca's Trixeo receives EU recommendation for asthma treatment
• Gentex Corporation (GNTX) Tops Q2 EPS by 8c ; Offers Guidance